Query Query
1. Query
Results
Date
7 substances in Reaxys
2017-10-19 09h:14m:01s (EST)
N
Search as: As drawn
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
1/24
2017-10-19 09:38:20
Reaxys ID 144260 View in Reaxys
1/7 CAS Registry Number: 493-92-5 Chemical Name: Prolintane; (+/-)-Prolintan; prolintane; 1-(1benzyl-butyl)-pyrrolidine; 1-(1-Benzyl-butyl)-pyrrolidin; 1-Phenyl-2-pyrrolidino-pentan; Prolintan; 1-Phenyl-2-pyrrolidino-pentan Linear Structure Formula: C15H23N Molecular Formula: C15H23N Molecular Weight: 217.354 Type of Substance: heterocyclic InChI Key: OJCPSBCUMRIPFL-UHFFFAOYSA-N Note:
N
Substance Label (5) Label References 1
Patent; Karl Thomae GmbH; DE1093799; (1957); Chem.Abstr.; nb. 19950; (1961), View in Reaxys; Rucker; Neugebauer; Zhong; Archiv der Pharmazie; vol. 325; nb. 1; (1992); p. 47 - 52, View in Reaxys
S-2 (racem.)
Yoshihara; Yoshimura; Chemical and Pharmaceutical Bulletin; vol. 20; (1972); p. 1906,1908-1910, View in Reaxys
3
Patent; Karl Thomae GmbH; DE1093799; (1957); Chem.Abstr.; nb. 19950; (1961), View in Reaxys
8
Patent; Karl Thomae GmbH; DE1093799; (1957); Chem.Abstr.; nb. 19950; (1961), View in Reaxys
4
Patent; Karl Thomae GmbH; DE1093799; (1957); Chem.Abstr.; nb. 19950; (1961), View in Reaxys
Patent-Specific Data (1) Location in Patent References Claim
Patent; Pharmaquest Ltd.; US6217904; (2001); (B1) English, View in Reaxys; Patent; Theobald, Frank; Frick, Ulrich; US2003/49308; (2003); (A1) English, View in Reaxys
Druglikeness (1) 1 of 1
LogP
3.824
H Bond Donors
0
H Bond Acceptors
1
Rotatable Bonds
5
TPSA
3.24
Lipinski Number
4
Veber Number
2
Highest Clinical Phase (1) Highest Clinical Phase Marketed Derivative (2) Comment (Derivative)
References
Hydrochlorid: F: 130-133grad
Yoshihara; Yoshimura; Chemical and Pharmaceutical Bulletin; vol. 20; (1972); p. 1906,1908-1910, View in Reaxys
Hydrochlorid: F: Patent; Karl Thomae GmbH; DE1093799; (1957); Chem.Abstr.; nb. 19950; (1961), View in Reaxys 133-134grad (aus Acn.) Boiling Point (2) Boiling Point [°C]
Pressure (Boiling Point) [Torr]
References
90 - 92
0.3
Patent; Thomae G.m.b.H.; GB814153; (1957), View in Reaxys; Patent; Thomae G.m.b.H.; DE1088962; (1960), View in Reaxys
153
16
Patent; Karl Thomae GmbH; DE1093799; (1957); Chem.Abstr.; nb. 19950; (1961), View in Reaxys
Chromatographic Data (1) Chromatographic References data
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
2/24
2017-10-19 09:38:20
LC (Liquid chromatography)
Jeong, Eun Sook; Kim, So-Hee; Cha, Eun-Ju; Lee, Kang Mi; Kim, Ho Jun; Lee, Sang-Won; Kwon, OhSeung; Lee, Jaeick; Rapid Communications in Mass Spectrometry; vol. 29; nb. 4; (2015); p. 367 - 384, View in Reaxys; Jeong, Eun Sook; Kim, So-Hee; Cha, Eun-Ju; Lee, Kang Mi; Kim, Ho Jun; Lee, SangWon; Kwon, Oh-Seung; Lee, Jaeick; Rapid Communications in Mass Spectrometry; vol. 29; nb. 4; (2015); p. 367 - 384, View in Reaxys
Further Information (1) Description (Fur- References ther Information) Further information
Reisch; Alfes; Moellmann; Die Pharmazie; vol. 23; nb. 5; (1968); p. 245 - 246, View in Reaxys
NMR Spectroscopy (1) 1 of 1
Description (NMR Spec- NMR troscopy) Yoshihara; Yoshimura; Chemical and Pharmaceutical Bulletin; vol. 20; (1972); p. 1906,1908-1910, View in Reaxys
Mass Spectrometry (4) Description (Mass Comment (Mass Spectrometry) Spectrometry)
References
electrospray ionisation (ESI); spectrum
Jeong, Eun Sook; Kim, So-Hee; Cha, Eun-Ju; Lee, Kang Mi; Kim, Ho Jun; Lee, Sang-Won; Kwon, Oh-Seung; Lee, Jaeick; Rapid Communications in Mass Spectrometry; vol. 29; nb. 4; (2015); p. 367 - 384, View in Reaxys
liquid chromatography mass spectrometry (LCMS); electrospray ionisation (ESI); spectrum
Jeong, Eun Sook; Kim, So-Hee; Cha, Eun-Ju; Lee, Kang Mi; Kim, Ho Jun; Lee, Sang-Won; Kwon, Oh-Seung; Lee, Jaeick; Rapid Communications in Mass Spectrometry; vol. 29; nb. 4; (2015); p. 367 - 384, View in Reaxys
HRMS (High resolution mass spectrometry); TOFMS (Time of flight mass spectrum); ESI (Electrospray ionisation); LCMS (Liquid chromatography mass spectrometry); Spectrum
Vonaparti; Lyris; Angelis; Panderi; Koupparis; Tsantili-Kakoulidou; Peters; Nielen; Georgakopoulos; Rapid Communications in Mass Spectrometry; vol. 24; nb. 11; (2010); p. 1595 - 1609, View in Reaxys
LCMS (Liquid chromatography mass spectrometry); ESI (Electrospray ionisation); Tandem mass spectrometry; Spectrum
mol peak
Thoerngren, John-Olof; Oestervall, Fredrik; Garle, Mats; Journal of Mass Spectrometry; vol. 43; nb. 7; (2008); p. 980 - 992, View in Reaxys
Use (14) Use Pattern
Location
References
Alzheimer's disease
Page/Page column 32
Patent; GOSFORTH CENTRE (HOLDINGS) PTY LTD.; BIRD, Philip; (34 pag.); US2016/815; (2016); (A1) English, View in Reaxys
Pharmaceuticals
Page/Page column 32
Patent; GOSFORTH CENTRE (HOLDINGS) PTY LTD.; BIRD, Philip; (34 pag.); US2016/815; (2016); (A1) English, View in Reaxys
dementia
Page/Page column 32
Patent; GOSFORTH CENTRE (HOLDINGS) PTY LTD.; BIRD, Philip; (34 pag.); US2016/815; (2016); (A1) English, View in Reaxys
mild cognitive impairment
Page/Page column 32
Patent; GOSFORTH CENTRE (HOLDINGS) PTY LTD.; BIRD, Philip; (34 pag.); US2016/815; (2016); (A1) English, View in Reaxys
treating a psychiatric disorder in combination with anti-epileptic agent
Page/Page column 32
Patent; GOSFORTH CENTRE (HOLDINGS) PTY LTD.; BIRD, Philip; (34 pag.); US2016/815; (2016); (A1) English, View in Reaxys
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
3/24
2017-10-19 09:38:20
psychostimulant
Patent; Poestges, Reiner; Schneider, Bernd; Ammer, Richard; US2008/75769; (2008); (A1) English, View in Reaxys
Attention Deficit Hyperactivity Disorder (ADHD)
Patent; Poestges, Reiner; Schneider, Bernd; Ammer, Richard; US2008/75769; (2008); (A1) English, View in Reaxys
Attention Deficit Hyperactivity Disorder (ADHD) comorbidities
Patent; Poestges, Reiner; Schneider, Bernd; Ammer, Richard; US2008/75769; (2008); (A1) English, View in Reaxys
narcolepsy
Patent; Poestges, Reiner; Schneider, Bernd; Ammer, Richard; US2008/75769; (2008); (A1) English, View in Reaxys
fatigue
Patent; Poestges, Reiner; Schneider, Bernd; Ammer, Richard; US2008/75769; (2008); (A1) English, View in Reaxys
cognitive decline associated with systemic diseases
Patent; Poestges, Reiner; Schneider, Bernd; Ammer, Richard; US2008/75769; (2008); (A1) English, View in Reaxys
acquired immunodeficiency syndrome
Patent; Poestges, Reiner; Schneider, Bernd; Ammer, Richard; US2008/75769; (2008); (A1) English, View in Reaxys
oncological diseases
Patent; Poestges, Reiner; Schneider, Bernd; Ammer, Richard; US2008/75769; (2008); (A1) English, View in Reaxys
Attention Deficit Disorder (ADD)
Patent; Poestges, Reiner; Schneider, Bernd; Ammer, Richard; US2008/75769; (2008); (A1) English, View in Reaxys
Isolation from Natural Product (1) Isolation from References Natural Product Nachw. in Arznei- Vidic; Schuette; Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft; vol. mittelgemischen 295; (1962); p. 342,358, View in Reaxys (nach Abtrennung durch Papierchromatographie) Medchem (57) 1 of 57
Target Mutant/Chimera Details
Sodium-dependent dopamine transporter [Mus musculus]:Wild
Substance Action on Target
Inhibitor
Target Species (Bioactivity)
Mus musculus
Target Subunit Proteins
Sodium-dependent dopamine transporter [Mus musculus]
Target Transfection
Non Transfected
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
Flux uptake
Biological Species/NCBI NMRI mouse; NMRI mouse ID Organs/Tissues
corpus striatum
Substance RN
144260View in Reaxys
Substance Name
prolintane
Measurement Parameter
ED50
Unit
µmol/kg
Quantitative value
55
Target, Subunit, Species Sodium-dependent dopamine transporter [Mus musculus]
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
4/24
2017-10-19 09:38:20
2 of 57
Target Subunit Synonyms
da transporter; dat; dat1; slc6a3; sodium-dependent dopamine transporter; solute carrier family 6 member 3
Target Uniprot ID
q61327
Compound RN
11305494; 1072822
Compound name
[3H]-Dopamine; Dopamine
Compound role
MAR; SUB
Target Mutant/Chimera Details
Sodium-dependent serotonin transporter [Mus musculus]:Wild
Substance Action on Target
Inhibitor
Target Species (Bioactivity)
Mus musculus
Target Subunit Proteins
Sodium-dependent serotonin transporter [Mus musculus]
Target Transfection
Non Transfected
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
Flux uptake
Biological Species/NCBI NMRI mouse; NMRI mouse ID Organs/Tissues
corpus striatum
Substance RN
144260View in Reaxys
Substance Name
prolintane
Measurement Parameter
ED50
Unit
µmol/kg
Qualitative value
>
Quantitative value
157
Target, Subunit, Species Sodium-dependent serotonin transporter [Mus musculus]
3 of 57
Target Subunit Synonyms
5ht transporter; 5htt; htt (sodium-dependent serotonin transporter); sert; slc6a4; sodiumdependent serotonin transporter; solute carrier family 6 member 4
Target Uniprot ID
q60857
Compound RN
143524; 143524
Compound name
5-HT; [14C]-5-HT
Compound role
SUB; MAR
Target Mutant/Chimera Details
Sodium-dependent serotonin transporter [Mus musculus]:Wild
Substance Action on Target
Inhibitor
Target Species (Bioactivity)
Mus musculus
Target Subunit Proteins
Sodium-dependent serotonin transporter [Mus musculus]
Target Transfection
Non Transfected
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
Flux uptake
Biological Species/NCBI NMRI mouse; NMRI mouse ID Organs/Tissues
corpus striatum
Substance RN
144260View in Reaxys
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
5/24
2017-10-19 09:38:20
Substance Name
prolintane
Measurement Parameter
% Inhibition
Unit
%
Quantitative value
39
Target, Subunit, Species Sodium-dependent serotonin transporter [Mus musculus]
4 of 57
Target Subunit Synonyms
5ht transporter; 5htt; htt (sodium-dependent serotonin transporter); sert; slc6a4; sodiumdependent serotonin transporter; solute carrier family 6 member 4
Target Uniprot ID
q60857
Measurement Object
at the Highest concentration
Compound RN
143524; 143524
Compound name
5-HT; [14C]-5-HT
Compound role
SUB; MAR
Substance Effect
Psychostimulant
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Substance RN
144260View in Reaxys
Substance Name
Prolintane
Measurement Parameter
Qualitative
Qualitative value
@
; (2012); Type: Review, Lab: EFF_071212, Owner: EFFECT, Number: 000, Revision: 07.12.2012 00:00:00, View in Reaxys 5 of 57
Bioassay Category
In Vivo (Animal models)
Bioassay Details
Effective dose against tetrabenazine induced sedative action in mice upon oral administration
Biological Species/NCBI Mus musculus ID Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
ED50
Unit
mg/kg
Qualitative value
=
Quantitative value
1.8
Remy; Van Saun Jr.; Lotti; Journal of medicinal chemistry; vol. 15; nb. 11; (1972); p. 1198 - 1198, View in Reaxys 6 of 57
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Plasma free fatty acid level in fatigued volunteers at 2.5 h following p.o. administration of compound (40 mg); Plasma FFA level = 522.4 uM/L (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Concentration
Unit
µM
Qualitative value
=
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
6/24
2017-10-19 09:38:20
Quantitative value
524.8
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
7 of 57
Measurement Object
Plasma free fatty acid level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Pulse rate in fatigued volunteers at 2 h following p.o. administration of compound (20 mg); Pulse rate = 74.5 (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
8 of 57
Measurement Object
pulse rate
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Glucose level in fatigued volunteers at 2.5 h following p.o. administration of compound (40 mg); Glucose level = 91.8 mg/100 mL (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
9 of 57
Measurement Object
Glucose level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Glucose level in fatigued volunteers at 2.5 h following p.o. administration of compound (20 mg); Glucose level = 93.5 mg/100 mL (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
10 of 57
Measurement Object
Glucose level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Systolic blood pressure in sitting position in fatigued volunteers at 2 h following p.o. administration of compound (20 mg); Value = 115.3 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
115.1
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
7/24
2017-10-19 09:38:20
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
11 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Systolic blood pressure in sitting position in fatigued volunteers at 3.5 h following p.o. administration of compound (40 mg); Systolic BP = 112.5 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
118.6
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
12 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in standing position in fatigued volunteers at 5 h following p.o. administration of compound (20 mg); Value = 81.3 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
84.5
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
13 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Systolic blood pressure in standing position in fatigued volunteers at 2 h following p.o. administration of compound (20 mg); Value = 120.8 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
116.7
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
14 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Systolic blood pressure in sitting position in fatigued volunteers at 5 h following p.o. administration of compound (40 mg); Systolic BP = 112.5 mm Hg (Pretreatment)
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
8/24
2017-10-19 09:38:20
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
118.6
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
15 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Plasma free fatty acid level in fatigued volunteers at 4.5 h following p.o. administration of compound (40 mg); Plasma FFA level = 522.4 uM/L (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Concentration
Unit
µM
Qualitative value
=
Quantitative value
605.4
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
16 of 57
Measurement Object
Plasma free fatty acid level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Glucose levels in fatigued volunteers at 4.5 h following p.o. administration of compound (20 mg); Glucose level = 93.5 mg/100 mL (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
17 of 57
Measurement Object
Glucose level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Pulse rate in fatigued volunteers at 5 h following p.o. administration of compound (20 mg); Pulse rate = 74.5 (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
18 of 57
Measurement Object
pulse rate
Bioassay Category
In Vitro (Efficacy)
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
9/24
2017-10-19 09:38:20
Bioassay Details
Plasma free fatty acid level in fatigued volunteers at 3.5 h following p.o. administration of compound (20 mg); Plasma FFA level = 489.8 uM/L (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Concentration
Unit
µM
Qualitative value
=
Quantitative value
540.8
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
19 of 57
Measurement Object
Plasma free fatty acid level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in sitting position in fatigued volunteers at 5 h following p.o. administration of compound (20 mg); Value = 74.0 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
78.7
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
20 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in standing position in fatigued volunteers at 2 h following p.o. administration of compound (20 mg); Value = 81.3 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
81.1
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
21 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Plasma free fatty acid level in fatigued volunteers at 1.5 h following p.o. administration of compound (40 mg); Plasma FFA level = 522.4 uM/L (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
10/24
2017-10-19 09:38:20
Measurement Parameter
Concentration
Unit
µM
Qualitative value
=
Quantitative value
532.1
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
22 of 57
Measurement Object
Plasma free fatty acid level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Glucose level in fatigued volunteers at 1.5 h following p.o. administration of compound (40 mg); Glucose level = 91.8 mg/100 mL (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
23 of 57
Measurement Object
Glucose level
Bioassay Category
In Vivo (Animal models)
Bioassay Details
Glucose level in fatigued volunteers at 1.5 h following p.o. administration of compound (20 mg); Glucose level = 93.5 mg/100 mL (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
24 of 57
Measurement Object
Glucose level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Glucose level in fatigued volunteers at 3.5 h following p.o. administration of compound (40 mg); Glucose level = 91.8 mg/100 mL (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
25 of 57
Measurement Object
Glucose level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Systolic blood pressure in sitting position in fatigued volunteers at 5 h following p.o. administration of compound (20 mg); Value = 115.3 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
11/24
2017-10-19 09:38:20
Unit
mmHg
Qualitative value
=
Quantitative value
122.5
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
26 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Glucose level in fatigued volunteers at 4.5 h following p.o. administration of compound (40 mg); Glucose level = 91.8 mg/100 mL (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
27 of 57
Measurement Object
Glucose level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in sitting position in fatigued volunteers at 3.5 h following p.o. administration of compound (40 mg); Diastolic BP = 71.6 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
77.4
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
28 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Systolic blood pressure in standing position in fatigued volunteers at 5 h following p.o. administration of compound (40 mg); Systolic BP = 114.9 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
120.2
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
29 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in sitting position in fatigued volunteers at 5 h following p.o. administration of compound (40 mg); Diastolic BP = 71.6 mm Hg (Pretreatment)
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
12/24
2017-10-19 09:38:20
Substance RN
144260View in Reaxys
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
77.4
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
30 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in standing position in fatigued volunteers at 5 h following p.o. administration of compound (40 mg); Diastolic BP = 82.4 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
85.2
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
31 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in sitting position in fatigued volunteers at 2 h following p.o. administration of compound (40 mg); Diastolic BP = 71.6 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
72.8
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
32 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Systolic blood pressure in standing position in fatigued volunteers at 3.5 h following p.o. administration of compound (40 mg); Systolic BP = 114.9 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
119.1
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
13/24
2017-10-19 09:38:20
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
33 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Pulse rate in fatigued volunteers at 2 h following p.o. administration of compound (40 mg); Pulse rate = 73.6 (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
34 of 57
Measurement Object
pulse rate
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Plasma free fatty acid level in fatigued volunteers at 1.5 h following p.o. administration of compound (20 mg); Plasma FFA level = 489.8 uM/L (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Concentration
Unit
µM
Qualitative value
=
Quantitative value
471
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
35 of 57
Measurement Object
Plasma free fatty acid level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in standing position in fatigued volunteers at 3.5 h following p.o. administration of compound (40 mg); Diastolic BP = 82.4 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
84.3
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
36 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Systolic blood pressure in standing position in fatigued volunteers at 3.5 h following p.o. administration of compound (20 mg); Value = 120.8 mm Hg (Pretreatment); Value = 120.8 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
14/24
2017-10-19 09:38:20
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
116.7
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
37 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in standing position in fatigued volunteers at 2 h following p.o. administration of compound (40 mg); Diastolic BP = 82.4 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
81.5
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
38 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Plasma free fatty acid level in fatigued volunteers at 4.5 h following p.o. administration of compound (20 mg); Plasma FFA level = 489.8 uM/L (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Concentration
Unit
µM
Qualitative value
=
Quantitative value
580.8
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
39 of 57
Measurement Object
Plasma free fatty acid level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Pulse rate in fatigued volunteers at 3.5 h following p.o. administration of compound (20 mg); Pulse rate = 74.5 (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
40 of 57
Measurement Object
pulse rate
Bioassay Category
In Vitro (Efficacy)
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
15/24
2017-10-19 09:38:20
Bioassay Details
Systolic blood pressure in sitting position in fatigued volunteers at 3.5 h following p.o. administration of compound (20 mg); Value = 115.3 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
116.1
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
41 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Systolic blood pressure in standing position in fatigued volunteers at 5 h following p.o. administration of compound (20 mg); Value = 120.8 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
123.6
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
42 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Plasma free fatty acid level in fatigued volunteers at 3.5 h following p.o. administration of compound (40 mg); Plasma FFA level = 522.4 uM/L (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Concentration
Unit
µM
Qualitative value
=
Quantitative value
527.5
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
43 of 57
Measurement Object
Plasma free fatty acid level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in sitting position in fatigued volunteers at 3.5 h following p.o. administration of compound (20 mg); Value = 74.0 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
16/24
2017-10-19 09:38:20
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
76.6
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
44 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vivo (Animal models)
Bioassay Details
Increase in blood pressure in human upon s.c. administration of compound (10 - 25 mg); Range = 10 - 20 mmHg
Substance RN
144260View in Reaxys
Substance Route of Adm.
subcutaneous administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
20
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
45 of 57
Measurement Object
Increase in BP
Bioassay Category
In Vivo (Animal models)
Bioassay Details
Systolic blood pressure in sitting position in fatigued volunteers at 2 h following p.o. administration of compound (40 mg); Systolic BP = 112.5 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
114.6
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
46 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Pulse rate in fatigued volunteers at 5 h following p.o. administration of compound (40 mg); Pulse rate = 73.6 (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
47 of 57
Measurement Object
pulse rate
Bioassay Category
In Vitro (Efficacy)
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
17/24
2017-10-19 09:38:20
Bioassay Details
Systolic blood pressure in standing position in fatigued volunteers at 2 h following p.o. administration of compound (40 mg); Systolic BP = 114.9 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
119.1
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
48 of 57
Measurement Object
systolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in standing position in fatigued volunteers at 3.5 h following p.o. administration of compound (20 mg); Value = 81.3 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
81.7
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
49 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Diastolic blood pressure in sitting position in fatigued volunteers at 2 h following p.o. administration of compound (20 mg); Value = 74.0 mm Hg (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Pressure
Unit
mmHg
Qualitative value
=
Quantitative value
74.1
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
50 of 57
Measurement Object
Diastolic blood pressure
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Pulse rate in fatigued volunteers at 3.5 h following p.o. administration of compound (40 mg); Pulse rate = 73.6 (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
18/24
2017-10-19 09:38:20
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
51 of 57
Measurement Object
pulse rate
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Plasma free fatty acid level in fatigued volunteers at 2.5 h following p.o. administration of compound (20 mg); Plasma FFA level = 489.8 uM/L (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Concentration
Unit
µM
Qualitative value
=
Quantitative value
493.2
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
52 of 57
Measurement Object
Plasma free fatty acid level
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Glucose level in fatigued volunteers at 3.5 h following p.o. administration of compound (20 mg); Glucose level = 93.5 mg/100 mL (Pretreatment)
Substance RN
144260View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
Qualitative
Hollister; Gillespie; The Journal of clinical pharmacology and the journal of new drugs; vol. 10; nb. 2; (1970); p. 103 - 109, View in Reaxys
53 of 57
Measurement Object
Glucose level
Bioassay Category
Pharmacokinetic
Bioassay Details
Percent of radioactivity excreted in rats urine in 48 h upon intraperitoneal administration of [3H]prolintane
Biological Species/NCBI Rattus norvegicus ID Substance RN
144260View in Reaxys
Substance Route of Adm.
intraperitoneal administration
Qualitative Results
57
Measurement Parameter
Ue (%)
Unit
%
Quantitative value
57
Yoshihara; Yoshimura; Xenobiotica; vol. 4; nb. 9; (1974); p. 529 - 535, View in Reaxys
54 of 57
Measurement Object
Percent of radioactivity excreted
Compound name
[3H]Prolintane
Compound role
RAD
Bioassay Category
Pharmacokinetic
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
19/24
2017-10-19 09:38:20
Bioassay Details
Percent dose excretion of pyrrolidine ring-opened metabolite in rats urine in 48 h upon intraperitoneal administration of [3H]prolintane
Biological Species/NCBI Rattus norvegicus ID Substance RN
144260View in Reaxys
Substance Route of Adm.
intraperitoneal administration
Qualitative Results
15
Measurement Parameter
Ue (%)
Unit
%
Quantitative value
15
Yoshihara; Yoshimura; Xenobiotica; vol. 4; nb. 9; (1974); p. 529 - 535, View in Reaxys
55 of 57
Compound name
[3H]prolintane
Compound role
COM
Bioassay Category
Pharmacokinetic
Bioassay Details
Percent dose excretion of p-hydroxyprolintane in rats urine in 48 h upon intraperitoneal administration of [3H]prolintane
Biological Species/NCBI Rattus norvegicus ID Substance RN
144260View in Reaxys
Substance Route of Adm.
intraperitoneal administration
Qualitative Results
5
Measurement Parameter
Ue (%)
Unit
%
Quantitative value
5
Yoshihara; Yoshimura; Xenobiotica; vol. 4; nb. 9; (1974); p. 529 - 535, View in Reaxys
56 of 57
Compound name
[3H]prolintane
Compound role
COM
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Compound (40 mg) was found to be less effective than amphetamine (20 mg) in fatigued volunteers
Substance RN
144260View in Reaxys
Measurement Parameter
Activity
Qualitative value
ND
John Krapcho; Annual reports in medicinal chemistry; vol. 6; (1970); p. 15 - 23, View in Reaxys 57 of 57
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Compound (40 mg) was found to be less effective than amphetamine (20 mg) in fatigued volunteers
Biological Species/NCBI Human ID Substance RN
144260View in Reaxys
Measurement Parameter
Activity
Qualitative value
ND
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
20/24
2017-10-19 09:38:20
John Krapcho; Annual reports in medicinal chemistry; vol. 6; (1970); p. 15 - 23, View in Reaxys
Reaxys ID 4905342 View in Reaxys
2/7 CAS Registry Number: 139925-42-1 Chemical Name: R-(+)-Prolintan Linear Structure Formula: C15H23N Molecular Formula: C15H23N Molecular Weight: 217.354 Type of Substance: heterocyclic InChI Key: OJCPSBCUMRIPFL-OAHLLOKOSA-N Note:
N
Substance Label (1) Label References R-1
Rucker; Neugebauer; Zhong; Archiv der Pharmazie; vol. 325; nb. 1; (1992); p. 47 - 52, View in Reaxys
Druglikeness (1) 1 of 1
LogP
3.824
H Bond Donors
0
H Bond Acceptors
1
Rotatable Bonds
5
TPSA
3.24
Lipinski Number
4
Veber Number
2
Derivative (1) Derivative R-(+)-Prolintanhydrochlorid
References Rucker; Neugebauer; Zhong; Archiv der Pharmazie; vol. 325; nb. 1; (1992); p. 47 - 52, View in Reaxys
Optical Rotatory Power (1) 1 of 1
Type (Optical Rotatory Power)
[alpha]
Concentration (Optical Rotatory Power)
9.6 g/100ml
Solvent (Optical Rotatory Power)
CH2Cl2
Optical Rotatory Power [deg]
7.6
Wavelength (Optical Ro- 589 tatory Power) [nm] Temperature (Optical Rotatory Power) [°C]
20
Rucker; Neugebauer; Zhong; Archiv der Pharmazie; vol. 325; nb. 1; (1992); p. 47 - 52, View in Reaxys
Reaxys ID 4905343 View in Reaxys
3/7 CAS Registry Number: 139925-46-5 Chemical Name: S-(-)-Prolintan Linear Structure Formula: C15H23N Molecular Formula: C15H23N Molecular Weight: 217.354 Type of Substance: heterocyclic
N
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
21/24
2017-10-19 09:38:20
InChI Key: OJCPSBCUMRIPFL-HNNXBMFYSA-N Note: Substance Label (1) Label References S-1
Rucker; Neugebauer; Zhong; Archiv der Pharmazie; vol. 325; nb. 1; (1992); p. 47 - 52, View in Reaxys
Druglikeness (1) 1 of 1
LogP
3.824
H Bond Donors
0
H Bond Acceptors
1
Rotatable Bonds
5
TPSA
3.24
Lipinski Number
4
Veber Number
2
Optical Rotatory Power (1) 1 of 1
Type (Optical Rotatory Power)
[alpha]
Concentration (Optical Rotatory Power)
8.8 g/100ml
Solvent (Optical Rotatory Power)
CH2Cl2
Optical Rotatory Power [deg]
-8
Wavelength (Optical Ro- 589 tatory Power) [nm] Temperature (Optical Rotatory Power) [°C]
20
Rucker; Neugebauer; Zhong; Archiv der Pharmazie; vol. 325; nb. 1; (1992); p. 47 - 52, View in Reaxys
Reaxys ID 3704624 View in Reaxys
4/7 CAS Registry Number: 1211-28-5 Chemical Name: Prolintan-hydrochloride; 1-(1-benzyl-butyl)pyrrolidine; hydrochloride; 1-(1-Benzyl-butyl)-pyrrolidin; Hydrochlorid; prolintane hydrochloride; Villescon; Promotil Linear Structure Formula: C15H23N*ClH Molecular Formula: C15H23N*ClH Molecular Weight: 253.815 Type of Substance: heterocyclic InChI Key: FKOFBBOQSMUYHD-UHFFFAOYSA-N Note:
N Cl
H
Substance Label (1) Label References 1*HCl
Rucker; Neugebauer; Zhong; Archiv der Pharmazie; vol. 325; nb. 1; (1992); p. 47 - 52, View in Reaxys
Druglikeness (1) 1 of 1
LogP
4.336
H Bond Donors
0
H Bond Acceptors
1
Rotatable Bonds
5
TPSA
3.24
Lipinski Number
4
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
22/24
2017-10-19 09:38:20
Veber Number
2
Melting Point (1) 1 of 1
Melting Point [°C]
134 - 135
Patent; Thomae G.m.b.H.; GB814153; (1957), View in Reaxys
Reaxys ID 4912250 View in Reaxys
5/7 CAS Registry Number: 139925-43-2 Chemical Name: R-(+)-Prolintan-hydrochlorid Linear Structure Formula: C15H23N*ClH Molecular Formula: C15H23N*ClH Molecular Weight: 253.815 Type of Substance: heterocyclic InChI Key: FKOFBBOQSMUYHD-XFULWGLBSA-N Note:
N Cl
H
Substance Label (1) Label References R-1*HCl
Rucker; Neugebauer; Zhong; Archiv der Pharmazie; vol. 325; nb. 1; (1992); p. 47 - 52, View in Reaxys
Druglikeness (1) 1 of 1
LogP
4.336
H Bond Donors
0
H Bond Acceptors
1
Rotatable Bonds
5
TPSA
3.24
Lipinski Number
4
Veber Number
2
Melting Point (1) 1 of 1
Melting Point [°C]
109 - 111
Solvent (Melting Point)
diethyl ether; aq. HCl
Rucker; Neugebauer; Zhong; Archiv der Pharmazie; vol. 325; nb. 1; (1992); p. 47 - 52, View in Reaxys
Reaxys ID 3779400 View in Reaxys
HO O
O
6/7 Chemical Name: 1-(1-benzyl-butyl)-pyrrolidine; oxalate; 1-(1Benzyl-butyl)-pyrrolidin; Oxalat Linear Structure Formula: C15H23N*C2H2O4 Molecular Formula: C2H2O4*C15H23N Molecular Weight: 307.39 Type of Substance: heterocyclic InChI Key: FINHMGHOBXLFSB-UHFFFAOYSA-N Note:
N
OH
Druglikeness (1) 1 of 1
LogP
3.136
H Bond Donors
2
H Bond Acceptors
5
Rotatable Bonds
6
TPSA
77.84
Lipinski Number
4
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
23/24
2017-10-19 09:38:20
Veber Number
2
Melting Point (1) 1 of 1
Melting Point [°C]
136 - 137
Patent; Thomae G.m.b.H.; DE1088962; (1960), View in Reaxys
Reaxys ID 3777308 View in Reaxys
O
O
7/7 Chemical Name: 1-(1-benzyl-butyl)-pyrrolidine; sulfate; 1-(1Benzyl-butyl)-pyrrolidin; Sulfat Linear Structure Formula: C15H23N*H2O4S Molecular Formula: C15H23N*H2O4S Molecular Weight: 315.434 Type of Substance: heterocyclic InChI Key: CVFSSAKHFIOBBJ-UHFFFAOYSA-N Note:
N
S HO
OH
Druglikeness (1) 1 of 1
LogP
2.06
H Bond Donors
2
H Bond Acceptors
5
Rotatable Bonds
5
TPSA
86.22
Lipinski Number
4
Veber Number
2
Melting Point (1) 1 of 1
Melting Point [°C]
102
Patent; Thomae G.m.b.H.; DE1088962; (1960), View in Reaxys
Copyright © 2017 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
24/24
2017-10-19 09:38:20